No. Cardarine (GW501516) is a PPAR-delta agonist, and WADA lists it under S4.4.1, not with the SARMs in S1.2. Its developer stopped work on it after cancers appeared in rats and mice at all doses tested.

Which is better studied, ostarine or RAD-140?

Ostarine, by far. Ostarine reached Phase 3 and has several controlled trials with results. RAD-140 has one published human trial, in 22 women with advanced breast cancer, and its muscle data come from animals.

Do RAD-140 and LGD-4033 have the same half-life?

No. RAD-140's half-life was about 45 hours in women with advanced breast cancer; LGD-4033's was 24 to 36 hours in healthy young men. The groups differ a lot, so treat the gap as approximate.

Can I share a comparison?

Yes. The page address keeps your choice (for example /compare/?a=ostarine&b=lgd-4033), so you can bookmark or send it.

Compare SARMs Side by Side: Evidence, Risks, Half-Life

Pick two compounds to see them side by side: what type of compound each is, its half-life, how far it got in clinical trials, its WADA status, how much it lowered testosterone in studies, its liver signal, the strength of the evidence and the side effects studies reported. Every cell comes from the Sarmguide database and links to its source.

Ostarine compared with LGD-4033
	Ostarine	LGD-4033
Type	SARM	SARM
Class	Selective androgen receptor modulator (SARM), nonsteroidal	Selective androgen receptor modulator (SARM), nonsteroidal
Half-life	~14–24 h source	24–36 h source
Research stage	Phase 3 source	Phase 2 source
Human studies	8	2
Approved as a medicine	No	No
WADA (sport)	Prohibited at all times source	Prohibited at all times source
Testosterone suppression	Moderate human data Yes, partly. In older men on 1–3 mg/day for 86 days, total testosterone fell by about 6–7 nmol/L vs placebo and SHBG fell on 3 mg. Free testosterone, LH and FSH did not change significantly. A 14-day Phase 1 study in healthy men (up to 30 mg/day) also found dose-dependent drops in SHBG and total testosterone, without a clinically significant change in free testosterone. source	Marked human data Yes, even at low doses. In healthy young men, 21 days of 0.1–1.0 mg/day lowered total testosterone and SHBG in a dose-dependent way. At 1.0 mg/day, FSH and free testosterone also fell. All hormones were back to baseline by day 56. This trial did not test doses above 1 mg/day. source
Liver signal	Moderate	Moderate
Strength of evidence	Strong	Moderate
Side effects reported	Lower total testosterone and SHBG trial source Lower HDL cholesterol trial source Raised liver enzymes trial source Drug-induced liver injury (cholestatic) case report source Liver and muscle damage with cardarine case report source Mislabeled products lab analysis source	Lower testosterone, SHBG and FSH trial source Lower HDL cholesterol trial source Drug-induced liver injury (cholestatic) case report source Combined effects with MK-677 in one user case report source Mislabeled products lab analysis source
Markers studies tracked	Total and free testosterone, LH and FSH, SHBG, Lipid panel (HDL, LDL, triglycerides), ALT/AST (liver enzymes), Bilirubin, Calcium	Total and free testosterone, LH and FSH, SHBG, Lipid panel (HDL, LDL, triglycerides), ALT/AST (liver enzymes), Bilirubin, PSA, Hematocrit

Where to buy (affiliate links)

Sarmguide is reader-supported. We may earn a commission from partner links. How we earn These listings are separate from the research above: they are the same whatever the result shows and are not a recommendation.

How the comparison works

Each row is read from the compound’s database record, the same data that powers its fact sheet. A small source marker next to a value links to the study or document behind it. “Not established” means we found no reliable human data, not that the risk is zero.

The suppression, liver and evidence rows are Sarmguide scores from 0 to 3, based on the cited studies; suppression is marked “human data” or “animal data”, and “Not measured” when there are no data. The side-effects row lists up to six findings with their evidence label (trial, case report, animal and so on), so a trial finding and a single case report never look the same.

After the table, a separate section headed “Where to buy (affiliate links)” shows the partner shop’s listings for the two compounds. It is the same whatever the table shows and is not a recommendation.

You can share a comparison: the page address keeps your choice, for example ostarine vs LGD-4033 or MK-677 vs tesamorelin.

What a side-by-side table cannot show

It lines up separate studies; it is not a head-to-head trial. Studies differ in dose, length and who took part (older adults, cancer patients, young men), so numbers in two columns are not directly comparable.
Half-lives come from different study designs. RAD-140’s figure (about 45 hours) comes from a trial in women with advanced breast cancer (LoRusso 2022); LGD-4033’s (24 to 36 hours) from healthy young men (Basaria 2013).
It does not cover combinations. For that, use the stack checker.

Written comparisons

For the most searched pairs we have full articles with the studies, the side effects and the reader reports in context:

Compare SARMs and Peptides Side by Side

Key takeaways